Castle Biosciences Exceeds 2025 Revenue Guidance with Strong Core Product Growth
CSTL has more than doubled off its 52-week low of $14.59.
Summary
Castle Biosciences announced preliminary unaudited Q4 and full-year 2025 results, expecting to exceed its revenue guidance and reporting significant growth in its core diagnostic tests.
Key Events · Earnings and Guidance · CSTL
-
Exceeded Revenue Guidance
2025 total revenue is expected to exceed $340 million, surpassing the previously guided range of $327-335 million.
-
Strong Core Product Growth
Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 37% for the full year 2025 and 42% in Q4 2025 year-over-year.
-
TissueCypher Volume Surge
TissueCypher Barrett's Esophagus test reports saw an 86% volume increase for the full year 2025 compared to 2024.
-
New Product Launch
AdvanceAD-Tx, a new test for atopic dermatitis, commenced a limited access launch in November 2025, with strong initial clinician adoption.
Analysis · CSTL · Industrial Applications And Services
The preliminary results indicate robust operational performance, with full-year 2025 revenue projected to surpass previous guidance. The substantial increase in test reports for core products like DecisionDx-Melanoma and TissueCypher, coupled with the successful limited launch of AdvanceAD-Tx, suggests strong market adoption and expansion opportunities. The healthy year-end cash position further strengthens the company's financial outlook for future growth initiatives.
At the time of this filing, CSTL was trading at $39.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $14.59 to $42.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.